Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients
Roberto Baldelli, Elisabetta Ferretti, Marie Lise Jaffrain-Rea, Gianluca Iacobellis, Giuseppe Minniti, Barbara Caracciolo, Carlo Moroni, Rosario Cassone, Alberto Gulino, Guido Tamburrano
Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
https://doi.org/10.1210/jc.84.2.527
10.1210/jc.84.2.527
Dive into the research topics of 'Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients'. Together they form a unique fingerprint.
Lanreotide Chemical Compounds 100%
lanreotide Medicine & Life Sciences 82%
Insulin-Like Growth Factor I Chemical Compounds 81%
Acromegaly Medicine & Life Sciences 64%
Somatostatin Medicine & Life Sciences 54%
Plasma Level Chemical Compounds 32%
Intramuscular Chemical Compounds 31%
Delayed-Action Preparations Medicine & Life Sciences 21%
Baldelli, R., Ferretti, E., Jaffrain-Rea, M. L., Iacobellis, G., Minniti, G., Caracciolo, B., Moroni, C., Cassone, R., Gulino, A., & Tamburrano, G. (1999). Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. Journal of Clinical Endocrinology and Metabolism, 84(2), 527-532. https://doi.org/10.1210/jc.84.2.527
Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. / Baldelli, Roberto; Ferretti, Elisabetta; Jaffrain-Rea, Marie Lise et al.
Baldelli, R, Ferretti, E, Jaffrain-Rea, ML, Iacobellis, G, Minniti, G, Caracciolo, B, Moroni, C, Cassone, R, Gulino, A & Tamburrano, G 1999, 'Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients', Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 2, pp. 527-532. https://doi.org/10.1210/jc.84.2.527
Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. Journal of Clinical Endocrinology and Metabolism. 1999;84(2):527-532. doi: 10.1210/jc.84.2.527
Baldelli, Roberto ; Ferretti, Elisabetta ; Jaffrain-Rea, Marie Lise et al. / Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. In: Journal of Clinical Endocrinology and Metabolism. 1999 ; Vol. 84, No. 2. pp. 527-532.
@article{30342875dbfd499a84bf31286d527b8f,
title = "Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients",
abstract = "Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.",
author = "Roberto Baldelli and Elisabetta Ferretti and Jaffrain-Rea, {Marie Lise} and Gianluca Iacobellis and Giuseppe Minniti and Barbara Caracciolo and Carlo Moroni and Rosario Cassone and Alberto Gulino and Guido Tamburrano",
doi = "10.1210/jc.84.2.527",
publisher = "The Endocrine Society",
T1 - Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients
AU - Baldelli, Roberto
AU - Ferretti, Elisabetta
AU - Jaffrain-Rea, Marie Lise
AU - Iacobellis, Gianluca
AU - Minniti, Giuseppe
AU - Caracciolo, Barbara
AU - Moroni, Carlo
AU - Cassone, Rosario
AU - Gulino, Alberto
AU - Tamburrano, Guido
N2 - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
AB - Cardiac involvement, mostly characterized by left ventricular hypertrophy associated with various degrees of cardiac dysfunction, greatly contributes to the increased mortality and morbidity observed in acromegaly. Lanreotide is a new SRIF analog characterized by a slow-release (SR) formulation with the peculiarity of a 30-mg im administration every 10-14 days. In this study, 13 patients with postoperative active acromegaly (9 females, 4 males, 45.9 ± 16.3 yr old) underwent an echo-Doppler and hormonal study before and during a 12-month period of treatment with SR-lanreotide. GH and insulin-like growth factor I plasma levels (mean ± SD) decreased significantly throughout the study period (from 10.1 ± 2.2 to 3.9 ± 0.9 ng/mL for GH, P <0.005; and from 511.0 ± 33.0 to 305.0 ± 34.2 ng/mL for insulin-like growth factor I, P <0.0001). Left ventricular mass index (mean ± SD, 137.1 ± 7.5 g/m2 at baseline) decreased after 3 months (120.0 ± 5.4 g/m2), 6 months (111.7 ± 5.7 g/m2), and 12 months (110.3 ± 5.2 g/m2) of treatment (P <0.005 at each time-point). This reduction in left ventricular mass index was accompanied by an improvement in some indexes of left ventricular diastolic function, especially the isovolumetric relaxation time (mean ± SD, 109.1 ± 4.6 m/sec at baseline), which decreased after 3 months (91.9 ± 2.8 m/sec), 6 months (92.3 ± 3.2 m/sec), and 12 months (92.2 ± 3.0 m/sec) of treatment (P <0.005 at each time-point). We conclude that SR- lanreotide is able to improve cardiac morphology and functional abnormalities in acromegaly; whether such beneficial effects on cardiac parameters will contribute to improve life expectancy in these patients should be further investigated.
U2 - 10.1210/jc.84.2.527
DO - 10.1210/jc.84.2.527